company background image
MBIO logo

Mustang Bio NasdaqCM:MBIO Stock Report

Last Price

US$0.94

Market Cap

US$9.7m

7D

-17.5%

1Y

-82.6%

Updated

27 Mar, 2024

Data

Company Financials +

MBIO Stock Overview

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

MBIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Mustang Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mustang Bio
Historical stock prices
Current Share PriceUS$0.94
52 Week HighUS$8.17
52 Week LowUS$0.90
Beta1.6
1 Month Change-27.13%
3 Month Change-30.88%
1 Year Change-82.61%
3 Year Change-98.11%
5 Year Change-98.16%
Change since IPO-99.36%

Recent News & Updates

Recent updates

Mustang Bio: This Horse May Gallop Still

Sep 23

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Aug 09
Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio: The Market Is Missing This Opportunity

May 03

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Dec 29
Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

Sep 14

Mustang Bio (MBIO) EHA Investor Presentations - Slideshow

Jun 18

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22
Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23
What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 28
Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Mustang Bio launches early-stage CAR T therapy study in brain tumor

Dec 21

Lindsay Rosenwald Is The Non-Executive Director of Mustang Bio, Inc. (NASDAQ:MBIO) And They Just Picked Up 100% More Shares

Dec 18
Lindsay Rosenwald Is The Non-Executive Director of Mustang Bio, Inc. (NASDAQ:MBIO) And They Just Picked Up 100% More Shares

Mustang Bio gains after impressing with ASH presentation

Dec 07

Is Mustang Bio (NASDAQ:MBIO) In A Good Position To Invest In Growth?

Dec 04
Is Mustang Bio (NASDAQ:MBIO) In A Good Position To Invest In Growth?

Mustang Bio EPS beats by $0.02

Nov 06

Shareholder Returns

MBIOUS BiotechsUS Market
7D-17.5%0.9%0.4%
1Y-82.6%10.3%28.8%

Return vs Industry: MBIO underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: MBIO underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is MBIO's price volatile compared to industry and market?
MBIO volatility
MBIO Average Weekly Movement9.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: MBIO's share price has been volatile over the past 3 months.

Volatility Over Time: MBIO's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201580Manny Litchmanhttps://www.mustangbio.com

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.

Mustang Bio, Inc. Fundamentals Summary

How do Mustang Bio's earnings and revenue compare to its market cap?
MBIO fundamental statistics
Market capUS$9.71m
Earnings (TTM)-US$51.60m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MBIO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$51.60m
Earnings-US$51.60m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did MBIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.